The development of the World War II fighter plane has lessons for how to manage innovation in healthcare.
I’ve always been an avid learner and found professional inspiration in historical accounts of the development of some of our culture’s earliest successes in innovation. Most recently, I’ve been captivated by stories of the Allied Forces’ air strategy during World War II, which many are learning about as AppleTV’s Masters of the Air unfolds each week.
In learning more about the innovation journey that inspired the P-51 Mustang — a critical fighter plane introduced during World War II — I found parallels to our industry and the innovation story being written in healthcare today.
The introduction of the P-51 Mustang marked a significant shift in the Allied bombing campaign. Previously, American bombers ventured into enemy airspace unaccompanied by fighter support and faced staggering losses from persistent enemy fighter attacks. But the Mustang changed that. Its ability to accompany bombers to and from their targets reduced loss rates significantly. By early 1944, with Mustangs escorting large-scale bombing missions, loss rates — once as high as 16% — often fell below 1%. This improvement was evident not only in the number of bombers and crewmembers saved. It also in boosted the morale of bomber crews, who felt more secure with the Mustang's presence. The Mustang increased the number of bombers reaching their intended targets, effectively crippling the German war machine's industrial capacity, and cementing its status as one of the most effective fighter escorts of the era.
What can healthcare leaders learn from the P-51 Mustang?
Every transformational innovation begins with a visionary leader. Dutch Kindelberger, the president of North American Aviation, recognized the need for a superior long-range fighter aircraft and was committed to achieving this goal. Edgar Schmued, an aeronautical engineer, was the brains behind turning the vision into reality. His designs combined cutting-edge aerodynamics with elegance, culminating in the iconic P-51 Mustang. Bob Chilton's daring test flights were crucial in validating the Mustang's design and capabilities. Each played an important role in bringing the P-51 Mustang to life.
At the core of innovation lies disruption. To drive change, effective leaders must be willing to make controversial decisions and question established norms. The P-51 Mustang faced the following significant obstacles:
So often the focus of innovation tends to focus on the creators and the products or solutions. The success of groundbreaking innovation often depends as much on its champion evangelists who take the initial concept and make it realize its transformative potential in the real world. In the Mustang’s story, an evangelist who stood out was Tommy Hitchcock, whose persistent advocacy led to critical improvements in the aircraft, most notably the integration of the Rolls-Royce Merlin engine. Further, he was instrumental in advocating for the need for a long-range fighter in front of British and American military leadership. Similarly, there were the aces of the sky such as Don Blakeslee who demonstrated the capabilities of the P-51 in combat and drove its wider adoption.
‘Black Thursday,' October 14, 1943, marked a critical moment for the P-51 Mustang. Following the heavy casualties suffered by American bombers during a raid on Schweinfurt, Germany, the need for a long-range fighter became evident. Robert Lovett, the assistant secretary of war for air, released a report underscoring this necessity. This situation set the stage for the Mustang to be reconsidered as a viable solution. Once given the opportunity, the P-51, with its new Merlin engine, exceeded expectations. Its long range, combined with superior speed and agility, allowed it to escort bombers deep into Europe and back, drastically reducing losses.
As healthcare leaders, be it as an incumbent organization building or scaling its innovation capability or a startup focused on creating novel solutions, we can take inspiration from the P-51 Mustang and the core elements of this breakthrough innovation story to advance our organizations, models of care and industry.
Feby Abraham, Ph.D., is executive vice president and chief strategy officer of Memorial Hermann Health System in Houston.
The 2024 Asembia Meeting is Underway
April 29th 2024GLP-1s, artificial intelligence and the Inflation Reduction Act are among the topics featured in the education sessions of the specialty pharmacy meeting in Las Vegas. The keynote speaker is William McRaven, a retired four-star admiral and former chancellor of the University of Texas system.
Read More
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
April 27th 2024This week, the FDA has approved several products, including Beqvez, the second gene therapy hemophilia B; Ojemda for children with brain tumors; an additional indication for Lutathera for adolescents with neuroendocrine tumors; and a bladder cancer immunotherapy. The agency has also issued a complete response letter for pz-cel to treat epidermolysis bullosa.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen